Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nichola Cooper

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Drug Design, Development and Therapy|June 3, 2021
A Review of Romiplostim Mechanism of Action and Clinical ApplicabilityJames B Bussel, Gerald Soff, Adriana Balduzzi, et al.
Platelets|November 4, 2022
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinibNichola Cooper, Waleed Ghanima, Quentin A Hill, et al.
Obstetric Medicine|April 12, 2018
Refractory severe immune thrombocytopenia in a twin pregnancyPatrick Harrington, Catherine Nelson-Piercy, Catherine Williamson, et al.
British Journal of Haematology|July 11, 2012
Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopeniaNichola Cooper, Roberto Stasi, Susanna Cunningham-Rundles, et al.
Seminars in Hematology|December 15, 2019
Mechanisms and therapeutic prospects of thrombopoietin receptor agonistsJames Bussel, Austin Kulasekararaj, Nichola Cooper, et al.
British Journal of Haematology|February 11, 2021
How I treat immune thrombocytopenia - a global viewNichola Cooper, Robert Bird, Yingyong Chinthammitr, et al.
Annals of Hematology|September 6, 2015
Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopeniaMarc Michel, Jeffrey Wasser, Bertrand Godeau, et al.
Blood|April 1, 2008
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximabRoberto Stasi, Nichola Cooper, Giovanni Del Poeta, et al.
Blood Reviews|June 28, 2024
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatmentJohn W Semple, Alexandra Schifferli, Nichola Cooper, et al.
Blood|June 6, 2007
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpuraRoberto Stasi, Giovanni Del Poeta, Elisa Stipa, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Drug Design, Development and Therapy|June 3, 2021
A Review of Romiplostim Mechanism of Action and Clinical ApplicabilityJames B Bussel, Gerald Soff, Adriana Balduzzi, et al.
Platelets|November 4, 2022
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinibNichola Cooper, Waleed Ghanima, Quentin A Hill, et al.
Obstetric Medicine|April 12, 2018
Refractory severe immune thrombocytopenia in a twin pregnancyPatrick Harrington, Catherine Nelson-Piercy, Catherine Williamson, et al.
British Journal of Haematology|July 11, 2012
Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopeniaNichola Cooper, Roberto Stasi, Susanna Cunningham-Rundles, et al.
Seminars in Hematology|December 15, 2019
Mechanisms and therapeutic prospects of thrombopoietin receptor agonistsJames Bussel, Austin Kulasekararaj, Nichola Cooper, et al.
British Journal of Haematology|February 11, 2021
How I treat immune thrombocytopenia - a global viewNichola Cooper, Robert Bird, Yingyong Chinthammitr, et al.
Annals of Hematology|September 6, 2015
Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopeniaMarc Michel, Jeffrey Wasser, Bertrand Godeau, et al.
Blood|April 1, 2008
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximabRoberto Stasi, Nichola Cooper, Giovanni Del Poeta, et al.
Blood Reviews|June 28, 2024
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatmentJohn W Semple, Alexandra Schifferli, Nichola Cooper, et al.
Blood|June 6, 2007
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpuraRoberto Stasi, Giovanni Del Poeta, Elisa Stipa, et al.
Pageof 15